Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| VERU INC.VERU · Entity 7234 | Chief Scientific Officer | August 13, 2026 | August 17, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
VERU INC.
Report date August 13, 2026 · Filed August 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,300 |
Reported balance
After 2026-08-13 transaction · row 1
1 source rowRow 1 · 2026-08-13 · Purchase · Acquired 1,800 · Balance 2,300 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 13, 2026 Filed Aug 17, 2026 20:26 UTC | VERU INC. VERU · Entity 7234 | PurchaseCommon Stock | 1,800 | $2.69 | $4,841.82 |
DisclosureSEC source: 0001042167-26-000060 · primary_doc.xml · nonDerivative · entry 1 BARNETTE K GARY · CIK 0001314913 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,300 Read SEC document |
| May 04, 2026 Filed May 6, 2026 19:59 UTC | VERU INC. VERU · Entity 7234 | GrantCommon Stock Option · Derivative | 160,000 | $0.00 Strike: $2.25 | $0.00 |
DisclosureSEC source: 0001042167-26-000038 · primary_doc.xml · derivative · entry 1 BARNETTE K GARY · CIK 0001314913 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 160,000 shares Expires 2036-05-04 F1 · derivative.exercise_date: Options for one-third of the shares vest on each of May 4, 2027, May 4, 2028 and May 4, 2029. Read SEC document |
| December 05, 2025 Filed Dec 9, 2025 17:29 UTC | VERU INC. VERU · Entity 7234 | GrantCommon Stock Option · Derivative | 27,000 | $0.00 Strike: $2.49 | $0.00 |
DisclosureSEC source: 0001042167-25-000072 · primary_doc.xml · derivative · entry 1 BARNETTE K GARY · CIK 0001314913 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 27,000 shares Expires 2035-12-05 F1 · derivative.exercise_date: Options for one-third of the shares vest on each of December 5, 2026, December 5, 2027 and December 5, 2028. Read SEC document |
| May 06, 2025 Filed May 8, 2025 19:29 UTC | VERU INC. VERU · Entity 7234 | GrantCommon Stock Option · Derivative | 104,000 | $0.00 Strike: $0.50 | $0.00 |
DisclosureSEC source: 0001042167-25-000027 · primary_doc.xml · derivative · entry 1 BARNETTE K GARY · CIK 0001314913 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 104,000 Underlying: Common Stock · 104,000 shares Expires 2035-05-06 F1 · derivative.exercise_date: Options for one-third of the shares vest on each of May 6, 2026, May 6, 2027 and May 6, 2028. Read SEC document |
| May 24, 2024 Filed May 24, 2024 22:57 UTC | VERU INC. VERU · Entity 7234 | PurchaseCommon Stock | 5,000 | $1.34 | $6,696.50 |
DisclosureSEC source: 0001042167-24-000043 · primary_doc.xml · nonDerivative · entry 1 BARNETTE K GARY · CIK 0001314913 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 F1 · price: The price reported above is the weighted average transaction price. The range of prices for such transactions is $1.32 to $1.34. Upon request by the Commission staff, the reporting person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| May 07, 2024 Filed May 9, 2024 20:02 UTC | VERU INC. VERU · Entity 7234 | GrantCommon Stock Option · Derivative | 102,000 | $0.00 Strike: $1.63 | $0.00 |
DisclosureSEC source: 0001042167-24-000036 · primary_doc.xml · derivative · entry 1 BARNETTE K GARY · CIK 0001314913 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,000 Underlying: Common Stock · 102,000 shares Expires 2034-05-07 F1 · derivative.exercise_date: Options are annual award grants for fiscal 2024 and options for one-third of the shares vest on each of May 7, 2025, May 7, 2026 and May 7, 2027. Read SEC document |
| May 09, 2023 Filed May 11, 2023 22:00 UTC | VERU INC. VERU · Entity 7234 | GrantCommon Stock Option · Derivative | 100,000 | $0.00 Strike: $1.37 | $0.00 |
DisclosureSEC source: 0001042167-23-000030 · primary_doc.xml · derivative · entry 1 BARNETTE K GARY · CIK 0001314913 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2033-05-09 F1 · derivative.exercise_date: Options for one-third of the shares vest on each of May 9, 2024, May 9, 2025 and May 9, 2026. Read SEC document |
| November 02, 2022 Filed Nov 4, 2022 21:16 UTC | VERU INC. VERU · Entity 7234 | GrantCommon Stock Option · Derivative | 98,000 | $0.00 Strike: $11.46 | $0.00 |
DisclosureSEC source: 0001042167-22-000060 · primary_doc.xml · derivative · entry 1 BARNETTE K GARY · CIK 0001314913 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,000 Underlying: Common Stock · 98,000 shares Expires 2032-11-02 F1 · derivative.exercise_date: Options are annual award grants for fiscal 2023 and options for one-third of the shares vest on each of November 2, 2023, November 2, 2024 and November 2, 2025. Read SEC document |
| April 22, 2022 Filed Apr 25, 2022 22:07 UTC | VERU INC. VERU · Entity 7234 | GrantCommon Stock Option · Derivative | 200,000 | $0.00 Strike: $11.21 | $0.00 |
DisclosureSEC source: 0001042167-22-000027 · primary_doc.xml · derivative · entry 1 BARNETTE K GARY · CIK 0001314913 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2032-04-22 F1 · derivative.exercise_date: Options for one-third of the shares vest on each of April 22, 2023, April 22, 2024 and April 22, 2025. Read SEC document |
| November 03, 2021 Filed Nov 5, 2021 16:02 UTC | VERU INC. VERU · Entity 7234 | GrantCommon Stock Option · Derivative | 134,800 | $0.00 Strike: $8.35 | $0.00 |
DisclosureSEC source: 0001042167-21-000082 · primary_doc.xml · derivative · entry 1 BARNETTE K GARY · CIK 0001314913 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,800 Underlying: Common Stock · 134,800 shares Expires 2031-11-03 F1 · derivative.exercise_date: Options for one-third of the shares vest on each of November 3, 2022, November 3, 2023 and November 3, 2024. Read SEC document |
| December 16, 2020 Filed Dec 19, 2020 02:07 UTC | VERU INC. VERU · Entity 7234 | SaleCommon Stock | 100,000 | $10.65 | $1,064,510.00 |
DisclosureSEC source: 0001042167-20-000066 · primary_doc.xml · nonDerivative · entry 1 BARNETTE K GARY · CIK 0001314913 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: The price reported above is the weighted average transaction price. The range of prices for such transactions is $10.440 to $10.847. Upon request by the Commission staff, the reporting person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| November 13, 2020 Filed Nov 17, 2020 17:26 UTC | VERU INC. VERU · Entity 7234 | GrantCommon Stock Option · Derivative | 112,500 | $0.00 Strike: $2.75 | $0.00 |
DisclosureSEC source: 0001042167-20-000047 · primary_doc.xml · derivative · entry 1 BARNETTE K GARY · CIK 0001314913 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 112,500 Underlying: Common Stock · 112,500 shares Expires 2030-11-13 F1 · derivative.exercise_date: Options for one-third of the shares vest on each of November 13, 2021, November 13, 2022 and November 13, 2023. Read SEC document |
| November 14, 2019 Filed Nov 18, 2019 17:03 UTC | VERU INC. VERU · Entity 7234 | GrantCommon Stock Option · Derivative | 137,808 | $0.00 Strike: $1.92 | $0.00 |
DisclosureSEC source: 0001042167-19-000094 · primary_doc.xml · derivative · entry 2 BARNETTE K GARY · CIK 0001314913 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,808 Underlying: Common Stock · 137,808 shares Expires 2029-11-14 F2 · derivative.exercise_date: Options for the shares vest on November 14, 2020. Read SEC document |
| November 14, 2019 Filed Nov 18, 2019 17:03 UTC | VERU INC. VERU · Entity 7234 | GrantCommon Stock Option · Derivative | 105,000 | $0.00 Strike: $1.92 | $0.00 |
DisclosureSEC source: 0001042167-19-000094 · primary_doc.xml · derivative · entry 1 BARNETTE K GARY · CIK 0001314913 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,000 Underlying: Common Stock · 105,000 shares Expires 2029-11-14 F1 · derivative.exercise_date: Options for one-third of the shares vest on each of November 14, 2020, November 14, 2021 and November 14, 2022. Read SEC document |
| May 13, 2019 Filed May 21, 2019 22:40 UTC | VERU INC. VERU · Entity 7234 | GrantCommon Stock Option · Derivative | 99,000 | $0.00 Strike: $1.60 | $0.00 |
DisclosureSEC source: 0001042167-19-000054 · primary_doc.xml · derivative · entry 1 BARNETTE K GARY · CIK 0001314913 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,000 Underlying: Common Stock · 99,000 shares Expires 2029-05-13 F1 · derivative.exercise_date: Options for one-third of the shares vest on each of May 13, 2020, May 13, 2021 and May 13, 2022. Read SEC document |
| December 18, 2018 Filed Dec 19, 2018 18:45 UTC | VERU INC. VERU · Entity 7234 | PurchaseCommon Stock | 50,000 | $1.51 | $75,500.00 |
DisclosureSEC source: 0001042167-18-000097 · primary_doc.xml · nonDerivative · entry 2 BARNETTE K GARY · CIK 0001314913 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Read SEC document |
| December 17, 2018 Filed Dec 19, 2018 18:45 UTC | VERU INC. VERU · Entity 7234 | PurchaseCommon Stock | 50,000 | $1.41 | $70,660.00 |
DisclosureSEC source: 0001042167-18-000097 · primary_doc.xml · nonDerivative · entry 1 BARNETTE K GARY · CIK 0001314913 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 F1 · price: The price reported above is the weighted average transaction price. The range of prices for such transactions is $1.369 to $1.42. Upon request by the Commission staff, the reporting person will provide full information regarding the number of shares sold at each separate price. Read SEC document |
| September 04, 2018 Filed Sep 5, 2018 22:16 UTC | VERU INC. VERU · Entity 7234 | GrantCommon Stock Option · Derivative | 300,000 | $0.00 Strike: $1.87 | $0.00 |
DisclosureSEC source: 0001042167-18-000078 · primary_doc.xml · derivative · entry 1 BARNETTE K GARY · CIK 0001314913 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2028-09-04 F1 · derivative.exercise_date: Options for one-third of the shares vest on each of September 4, 2019, September 4, 2020 and September 4, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.